|
|
|
|
Pharmaceutical development is as much an art as it is a science, with experts working to find the best solutions and then formulating them in a manner that is universally accessible, efficacious, and sustainable. This article delves into how customized release for dispersed dosage formats enhances patient acceptance and therapeutic performance.
|
|
|
|
|
Following the release of the FDA’s guidance on Nitrosamine Drug Substance-Related Impurities, sponsors need to adopt a systematic approach for identifying susceptible APIs. Examine a new methodology that holds significant promise, enabling manufacturers to prioritize risk mitigation and ensure compliance with upcoming regulatory deadlines.
|
|
|
|
|
Medication adherence is influenced by several factors, including the method of treatment, healthcare accessibility, a patient’s socioeconomic status, and the palatability and swallowability of a drug. For pediatric populations, adherence can be complicated by additional considerations. By partnering with an experienced CDMO, companies can increase acceptability of their drugs among pediatric patients.
|
|
|
|
|
|
Capacity Update May 2024: APl and HPAPI Development
|
An outsourcing partner with services from the earliest phases of development and formulation all the way to manufacturing and packaging pays tremendous dividends in terms of working with the same teams and the same points of contact throughout your product's full journey. This, in turn, helps you get your product to market with significant savings in costs and time.
|
|
• Request Information
|
|
|
|
|
|
|
|
